IL307997A - Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases - Google Patents

Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Info

Publication number
IL307997A
IL307997A IL307997A IL30799723A IL307997A IL 307997 A IL307997 A IL 307997A IL 307997 A IL307997 A IL 307997A IL 30799723 A IL30799723 A IL 30799723A IL 307997 A IL307997 A IL 307997A
Authority
IL
Israel
Prior art keywords
treatment
drug delivery
delivery systems
pharmaceutical preparations
eye diseases
Prior art date
Application number
IL307997A
Other languages
English (en)
Hebrew (he)
Inventor
Cheng-Wen Lin
Angela Dawn Glendenning
Sevgi Gurkan
Original Assignee
Perfuse Therapeutics Inc
Lin Cheng Wen
Angela Dawn Glendenning
Sevgi Gurkan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc, Lin Cheng Wen, Angela Dawn Glendenning, Sevgi Gurkan filed Critical Perfuse Therapeutics Inc
Publication of IL307997A publication Critical patent/IL307997A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL307997A 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases IL307997A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182559P 2021-04-30 2021-04-30
US202163287737P 2021-12-09 2021-12-09
PCT/US2022/027048 WO2022232588A1 (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
IL307997A true IL307997A (en) 2023-12-01

Family

ID=83848732

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307997A IL307997A (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Country Status (10)

Country Link
US (3) US11786510B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515826A (cg-RX-API-DMAC7.html)
KR (1) KR20240004643A (cg-RX-API-DMAC7.html)
AU (1) AU2022264036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022705A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218251A1 (cg-RX-API-DMAC7.html)
IL (1) IL307997A (cg-RX-API-DMAC7.html)
MX (1) MX2023012723A (cg-RX-API-DMAC7.html)
WO (1) WO2022232588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
AU2024405327A1 (en) * 2023-12-20 2026-07-02 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6573285B2 (en) * 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
AR080888A1 (es) 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
ES2813383T3 (es) 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) * 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10905770B2 (en) * 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Also Published As

Publication number Publication date
BR112023022705A2 (pt) 2024-01-16
US20260130890A1 (en) 2026-05-14
MX2023012723A (es) 2024-02-08
KR20240004643A (ko) 2024-01-11
US11786510B2 (en) 2023-10-17
US20230105507A1 (en) 2023-04-06
US12622894B2 (en) 2026-05-12
CA3218251A1 (en) 2022-11-03
JP2024515826A (ja) 2024-04-10
WO2022232588A1 (en) 2022-11-03
AU2022264036A1 (en) 2023-11-23
US20230414577A1 (en) 2023-12-28
EP4329753A1 (en) 2024-03-06
EP4329753A4 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
IL284733A (en) Pharmaceutical delivery compositions and uses thereof
IL286539A (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
EP3941561A4 (en) SYSTEM FOR NASAL DRUG ADMINISTRATION
EP3761864A4 (en) CORE-SHELL MICRONEEDLE PLATFORM FOR TRANSDERMAL AND PULSATIL DRUG/VACCINE DELIVERY AND METHODS OF MANUFACTURE THEREOF
IL272105A (en) Local administration of pharmaceutical agents containing cell-penetrating peptides for use in the treatment of age-related macular degeneration and other eye diseases
EP3700617A4 (en) SYSTEMS AND METHODS FOR ADMINISTERING NEUROR-REGENERATIVE THERAPY
MA55452A (fr) Systèmes et procédés d'administration de médicament
EP3731846A4 (en) DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTION
EP3831944A4 (en) MONOCLONAL ANTIROR1 ANTIBODY, FUNCTIONAL FRAGMENT OF IT, GENE, DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
EP3836866A4 (en) SYSTEMS FOR ENTERIC DELIVERY OF THERAPEUTICS
EP3324944A4 (en) INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
EP3962661A4 (en) DEVICES AND METHODS FOR NASAL DRUG OR AGENTS DELIVERY
IL285073A (en) Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
EP4329753A4 (en) PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
EP3362096A4 (en) OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EP3313379A4 (en) ORAL PHARMACEUTICAL FORM FOR THE DISTRIBUTION OF A PEPTIDE AND / OR PROTEIN
TWI925870B (zh) 護理點藥物遞送設備
EP4021369A4 (en) Medical devices for continuous delivery of therapeutic agents
IL311382A (en) Drug administration system for local delivery of therapeutic substances and their uses
EP3765122A4 (en) MEDICAL INSTRUMENT AND MEDICAL PROCEDURE FOR LOCALIZED ACTIVE SUBSTANCE RELEASE
EP3956350A4 (en) ENGINEERED CRY PROTEINS FOR ADMINISTRATION OF THERAPEUTICS